Anti‐tumor effects of a nonsteroidal anti‐inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator‐activated receptor gamma and suppressing matrix metalloproteinase‐2 expression
Open Access
- 23 March 2018
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 7 (5) , 1944-1954
Abstract
Surgical resection is the only treatment for chondrosarcomas, because of their resistance to chemotherapy and radiotherapy; therefore, additional strategies are crucial to treat chondrosarcomas. Peroxisome proliferator‐activated receptor gamma (PPARγ) is a ligand‐activated transcription factor, which has been reported as a possible therapeutic target in certain malignancies including chondrosarcomas. In this study, we demonstrated that a nonsteroidal anti‐inflammatory drug, zaltoprofen, could induce PPARγ activation and elicit anti‐tumor effects in chondrosarcoma cells. Zaltoprofen was found to induce expressions of PPARγ mRNA and protein in human chondrosarcoma SW1353 and OUMS27 cells, and induce PPARγ‐responsible promoter reporter activities. Inhibitory effects of zaltoprofen were observed on cell viability, proliferation, migration, and invasion, and the activity of matrix metalloproteinase‐2 (MMP2); these effects were dependent on PPARγ activation and evidenced by silencing PPARγ. Moreover, we showed a case of a patient with cervical chondrosarcoma (grade 2), who was treated with zaltoprofen and has been free from disease progression for more than 2 years. Histopathological findings revealed enhanced expression of PPARγ and reduced expression of MMP2 after administration of zaltoprofen. These findings demonstrate that zaltoprofen could be a promising drug against the malignant phenotypes in chondrosarcomas via activation of PPARγ and inhibition of MMP2 activity.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP15K10435, JP17K16682)
This publication has 39 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Calcium Channel TRPV6 as a Potential Therapeutic Target in Estrogen Receptor–Negative Breast CancerMolecular Cancer Therapeutics, 2012
- The use of Cox-2 and PPARγ signaling in anti-cancer therapiesExperimental and Therapeutic Medicine, 2010
- The Peroxisome Proliferator-Activated Receptor γ/Retinoid X Receptor α Heterodimer Targets the Histone Modification Enzyme PR-Set7/Setd8 Gene and Regulates Adipogenesis through a Positive Feedback LoopMolecular and Cellular Biology, 2009
- Chondrosarcoma and Peroxisome Proliferator‐Activated ReceptorPPAR Research, 2008
- Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell lineActa Pharmacologica Sinica, 2007
- Gelatinase-mediated migration and invasion of cancer cellsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2005
- Matrix Metalloproteinase Inhibitors and Cancer—Trials and TribulationsScience, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Risk factors for survival and local control in chondrosarcoma of boneThe Journal of Bone and Joint Surgery. British volume, 2002